StudyFinder

A multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction ≥ 40% (LVEF ≥ 40%)

Recruiting

This study is a randomized, double-blind, parallel-group, placebo-controlled, multicenter, event-driven Phase 3 study with independently adjudicated clinical outcome assessments.

I'm interested

This study is NOT accepting healthy volunteers

Heart Failure

Heart Failure with Preserved Ejection Fraction,, Mineralocorticoid receptor antagonist (MRA)

Marlene Romero - mlromero@healtheast.org
Les Forgosh
Phase III
STUDY00012258
NCT04435626
See this study on ClinicalTrials.gov

Back